BICX BioCorrx Inc

BioCorRx Announces the Launch of UnCraveRx On-Demand Virtual Fitness, Lifestyle Support and Nutrition App

BioCorRx Announces the Launch of UnCraveRx On-Demand Virtual Fitness, Lifestyle Support and Nutrition App

ANAHEIM, CA, July 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that it has launched the UnCraveRx™ virtual app. UnCraveRx™ is a medically assisted weight loss management program that helps to reduce food cravings combined with on-demand virtual lifestyle support, fitness and nutrition.

The estimated launch of the full UnCraveRx™ program is October 2019, but the UnCraveRx™ App is available now. It is available online  or through the Android or iOS app stores. The app includes fitness classes that cover a range of fitness styles and interests, nutrition and lifestyle support. The app also offers other wellness trackers.

Lourdes Felix, CFO, COO and Director, stated, “The UnCraveRx™ app fits people of all ages and stages of life, and provides a personalized experience that can help to eliminate many time barriers for meal planning and regular physical activity. No matter what kind of incentive or daily reminders you need to meet your goals, you can find an option to keep yourself on track. Our aim is to inspire better overall wellness for real people and support their weight loss and weight management goals with lifestyle support groups.”

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance use; please visit  for more information on the BioCorRx Recovery Program. The UnCraveRx™ Weight Loss Program is also a medication assisted program; please visit  for more information on UnCraveRx™. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit . 

BioCorRx Inc.



714-462-4880



Investor Relations:

Crescendo Communications, LLC

(212) 671-1020 x304

EN
22/07/2019

Underlying

BICXBioCorrx Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCorrx Inc

 PRESS RELEASE
Free
BICX BIOCORRX INC

BioCorRx Reports Business Update for the Second Quarter of 2024

BioCorRx Reports Business Update for the Second Quarter of 2024 ANAHEIM, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2024, and reported on recent corporate developments. Additionally, BioCorRx Inc. announces the expansion of its intellectual property portfolio with a new international patent awarded from Israel for the treatment of weight loss. This patent covers the use of a subcut...

August 15, 2024 1 EN
 PRESS RELEASE
Free
BICX BIOCORRX INC

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to...

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia ANAHEIM, CA, April 03, 2024 (GLOBE NEWSWIRE) -- via --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and Trademark Office (USPTO). The USPTO has issued U.S. Patent No. 11,793,801 entitled, “Treatment of Pain and Neurologi...

April 3, 2024 1 EN
 PRESS RELEASE
Free
BICX BIOCORRX INC

BioCorRx Reports Business Update for 2023

BioCorRx Reports Business Update for 2023 ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments. Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet designed for treating opioid ...

April 2, 2024 1 EN
 PRESS RELEASE
Free
BICX BIOCORRX INC

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 ...

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD ANAHEIM, CA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc. has been awarded a 3-year grant for approximately $11 million from the National Institute on Drug Abuse (NIDA), part of the National Institut...

February 28, 2024 1 EN
 PRESS RELEASE
Free
BICX BIOCORRX INC

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarne...

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors. Dr. DeVarney spearheaded the development of Probuphine® (buprenorphine implant), the first six-month, subcutaneous implant approved in the United States, Canada, a...

February 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch